| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ß3
From the Departments of Geriatrics,* Cardiovascular Genome Science, and Cardiology, ¶ Nagoya University Graduate School of Medicine, Nagoya, Japan; the Cardiovascular Department, College of Medical, Yanbian University, Yanji, China; and Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
or interleukin-ß1 significantly augmented the ability of SMC membranes to degrade elastin along with a significant increase in the level of active Cat S compared with controls. Immunofluorescence and confocal microscopy showed a punctuated pattern of Cat S clusters at the periphery of SMCs; further studies demonstrated partial co-localization of Cat S and integrin 
ß3 at the cell surfaces. These findings demonstrate that active Cat S co-localizes with integrin ß3 as a receptor on the SMC surface, playing an important role in the invasive behavior of SMCs.
Recent studies have shown that cathepsin (Cat) S and Cat K are overexpressed in SMCs of atherosclerotic and neointimal lesions in humans and animals.6,10,11 It has also been reported that Cat S has potent elastolytic activity as well as collagenolytic activity, and Cat S-deficiency markedly reduced content of intimal SMCs and fragmentation of elastic lamina in aortas of atherosclerotic lesions.6,7,10-12 These observations may indicate that the interaction of Cat S released from SMCs with ECM proteins is involved in SMC migration or vascular remodeling, a process that likely occurs in the development of atherosclerotic and intimal lesions. However, it remains unclear whether cathepsins released from SMCs really contribute to the SMC migration through ECM proteins. Generally, during the process of cell migration through ECM proteins, the proteolysis is counterproductive for the cell migration. Therefore, these enzymes are usually localized to receptors, adhesion sites, or invasive protrusions of cells where ECM degradation takes place. This localization concentrates their activity in close proximity to their substrates. By concentrating proteolytic events at or near the cell surface, these processes can be effective even in the presence of high concentrations of inhibitors.13,14 At present it remains unknown how SMC-derived Cat S interacts with ECM components during SMC migration through ECM. In addition, it remains unresolved whether cathepsins are associated with the SMC surface close to the substrates or whether they are localized to the specific receptors.
In the present study, we examined whether cathepsins derived from SMCs are involved in the SMC invasion through collagen and elastin substrates. In addition, we further analyzed the intracellular distribution of cathepsins in cultured SMCs and tried to identify their localization on the SMC surface as well as their molecular functions.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Morpholinurea-leucine-homophenylalanine-vinylsulfone-phenyl (LHVS) was purchased from Arris Pharmaceutical Inc. Trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E64) was purchased from Molecular Probes Inc., Eugene, OR. Peptide hydroxamic acid (GM6001) and Alexa Fluor goat anti-mouse IgG (H+L) were purchased from Calbiochem, La Jolla, CA. Phenylmethyl sulfonyl fluoride (PMSF) and monoclonal anti-Cat L (mAb Cat L) were purchased from Sigma-Aldrich, St. Louis, MO. Recombinant human cystatin C (Cyst C) was purchased from Biotrend Chemikalien GmbH (Köln, Sweden). Mouse monoclonal anti-ß3 (mAb LM609) was purchased from Chemicon International Inc., Temecula, CA Antibodies to human Cat S and Cat K were raised from rabbits as previously described (for Western blot, immunofluorescence, immunoprecipitation).6
Rabbit polyclonal anti-Cat B (pAb Cat B) was purchased from Upstate Biotechnology, Lake Placid, NY. Goat polyclonal anti-Cat D (pAb Cat D) and anti-integrin ß5 (pAb ß5) were purchased from Santa Cruz Biotechnology, Santa Cruz, CA. Anti-goat and anti-rabbit IgG (H+L)-FITC were purchased from Medical & Biological Laboratories Co., Ltd. (Nagoya, Japan). Mouse monoclonal anti-integrin (mAb ), ß1 (mAb ß1), and ß3 (mAb ß1) were purchased from BD Biosciences Pharmingen.
Cell Culture
Human aortic SMCs (HSMCs, BioWhittaker, Walkersville, MD) were subcultured at passages 4 to 6 for the following experiments in SmBM supplemented with SmGM-2 Single Quots (both from Cambrex BioScience, Walkersville, MD). Both rat and bovine SMCs (RSMCs and BSMCs) were obtained from the media of rat and calf aortas by the tissue explant method and were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum.15
Migration and Invasion Assay
SMC migration and invasion were assessed with a modified Boyden chamber and platelet-derived growth factor-BB (Peprotech Ltd., London, UK) as a chemoattractant (10 ng/ml).8 For the migration assay, the membrane was coated with 100 µg/ml of type I collagen (BD Biosciences) or Etna-Elastin (Elastin Products Co., Inc.); for the invasion assay, the membrane was coated with 20 µl of type I collagen (1 mg/ml) or Etna-Elastin (15 mg/ml) solution. HSMC migration (6 hours) and invasion assays (12 hours) were performed in the presence or absence of a selective Cat S inhibitor (LHVS, 5 nmol/L), a broader-spectrum CP inhibitor (E64, 20 µmol/L), an endogenous CP inhibitor (Cyst C, 1 µg/ml), an MMP inhibitor (GM6001, 10 µmol/L), and an SP inhibitor (PMSF, 2 mmol/L) for 6 hours (12 hours for PMSF). Migrated and invaded cells were counted in eight randomly chosen fields of duplicate chambers (n = 10) at x200 magnification for each sample.
Cell Adhesion Assay
The 96-well plates were coated with type I collagen, denatured type I collagen (each 5 µg/50 µl in 0.02 N acetic acid per well), vitronectin [1 µg/50 µl phosphate-buffered saline (PBS) per well] or Etna-Elastin (1 µg/50 µl Dulbecco’s modified Eagle’s medium per well), and nonspecific binding was blocked with 10% bovine serum albumin (BSA). HSMC adhesion was performed in the presence or absence of several protease inhibitors as described above. Procedural details are described elsewhere.16 To examine the effect of the soluble human recombinant active form of Cat S (R&D Systems, Inc., Minneapolis, MN) on the attachment of HSMCs to matrix proteins, HSMCs were pretreated in the presence or absence of the active form of Cat S (0 to 5 µg/ml) for 30 minutes at 37°C and then seeded onto matrix protein-coated wells, followed by adhesion assay as described above.
Isolation of Plasma Membrane
After being cultured in the serum-free condition (24 hours, 90% confluent), cells were solubilized in 25 mmol/L Tris-HCl (pH 7.4) containing 8.5% sucrose, 50 mmol/L NaCl, and 1 mmol/L PMSF (lysis buffer) and sonicated. After removal of the insolubilized material by centrifugation at 500 x g for 5 minutes, the supernatant was then centrifuged at 100,000 x g for 2 hours at 4°C. The supernatants were concentrated with YM-10 Centricon filters (Millipore Corp., Bedford, MA) as the cytosol fractions for the following Western blot analysis and elastase assay. The pellets was resuspended in lysis buffer without sucrose and separated further on a discontinuous sucrose gradient (20, 30, 50, and 60% sucrose in water) centrifuged at 100,000 x g for 2 hours. The plasma membrane-enriched fraction, appearing as a visible band at the 30/50% sucrose interface, was collected as previously described,17 pelleted at 100,000 x g for 2 hours, and then suspended at a concentration of 4 to 6 mg/ml protein for Western blotting analysis and elastase assay.
Biotinylation of Cell Surface Protein and Avidin-Agarose Extraction
SMCs (2 x 107 cells) cultured in serum-free media for 24 hours were washed with ice-cold PBS twice and incubated with 0.5 mg/ml EZ Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL) at 4°C for 30 minutes. After biotinylation of the cell surface, the cells were washed extensively using quenching buffer (20 mmol/L Tris-HCl and 120 mmol/L NaCl, pH 7.4) to remove excess biotin, sonicated, and centrifuged at 500 x g for 5 minutes. After the addition of avidin-agarose beads to the supernatant (Pierce) and incubation overnight at 4°C, the proteins that bound to the avidin-agarose beads were washed with RIPA buffer (Upstate Biotechnology) six times and were solubilized in the sample buffer for Western blotting analysis.
Immunoprecipitation
Immunoprecipitation was performed as previously described.18
In brief, after rinsing with PBS, SMCs were solubilized at 107 cells/ml in lysis buffer [40 mmol/L Tris-HCl, pH 7.4, 10 mmol/L NaCl, 0.5 (v/v) Triton X-100, 1 mmol/L PMSF, 2 mmol/L ethylenediaminetetraacetic acid] and sonicated on ice. Insolubilized material was removed by centrifugation as described above. After preclearing with protein A-Sepharose or protein G-Sepharose (both from Sigma-Aldrich), the resulting samples (250 µl) were incubated with 3 µg of mAb LM609, mAb ß1, mAb ß3, pAb ß5, or pAb Cat S. The immune complexes were collected on protein G-Sepharose (for ß3, , ß1, and ß3) or protein A-Sepharose (for ß5 and Cat S) during 2 hours of incubation at room temperature. After being washed for six times, the beads were treated with reducing sample buffer and boiled. Eluted proteins were analyzed by Western blot.
Western Blot Analysis
The procedures for preparing SMC plasma membrane fractions and cytosol fractions were identical to those described above. The conditioned media from serum-free cultured SMCs (24 hours) were collected and concentrated with YM-10 Centricon filters. Equal amounts of protein from each sample were separated on 6% (for integrins and ß3) or 15% (for Cat S, K, B, L, and D) sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto polyvinylidene difluoride membrane as previously described.10,19
Immunoblotting used antibodies specific to integrins ( and ß3) and cathepsins (Cat S, K, B, L, D). We also examined the Cat S and Cat K content of fractions of the plasma membrane, cytosol, and media of HSMCs stimulated with and without interferon- (IFN-, 400 U/ml) or interleukin-1ß (IL-1ß, 10 ng/ml; Genzyme Corp., Cambridge, MA), respectively.
Immunocytofluorescence
For single-staining, after the attachment of SMCs (cells density at 2 x 104/ml) to coverslips precoated with type I collagen, SMCs were fixed for 10 minutes with 8% paraformaldehyde in PBS, washed, and permeabilized for 6 minutes with 0.5% Triton X-100. The cells were subsequently treated as follows. After washing with PBS-glycerol and blocking with 3% BSA/PBS, they were incubated with primary antibodies (1:100, Cat S, K, B, L, and D) for 40 minutes at room temperature, washed with 0.1% BSA/PBS, incubated with fluorescein isothiocyanate (FITC) green-conjugated (1:400, for Cat S, K, D, and B) or Alexa Fluor red-conjugated (1:200, for Cat L and integrin ß3) secondary antibodies for 40 minutes at room temperature, and washed with PBS. We also performed single immunostaining for SMCs stimulated with rat, bovine, and human recombinant IFN- (400 U/ml, R&D Systems, Inc.; Serotec Ltd., Oxford, UK) for 24 hours. For double staining, the cells were treated with a mixture of two primary antibodies (Cat S and integrin ß3) and stained as described above. For negative controls, rabbit and goat IgG were used as first antibodies. Coverslips were treated with Prolong mounting medium (Molecular Probes) and visualized by confocal microscopy.
Cat S Binding Assay
Cat S binding assays were performed as described,19
with modifications. Briefly, wells of 96-well plates were precoated with 75 µl of human recombinant integrin ß3 (Chemicon International, Inc.) and BSA at 2 µg/ml in binding buffer (20 mmol/L Tris-HCl, 150 mmol/L NaCl, and 1 mmol/L CaCl2, pH 7.4) overnight at 4°C. After being washed three times with PBS, the plates were blocked with 10% BSA in PBS for 1 hour and then washed with PBS. A total of 100 µl of the human recombinant active form of Cat S (4 µg/ml) in 1% BSA/PBS was added to the precoated wells. After overnight incubation at 4°C, the wells were washed three times with PBS. Bound material was solubilized with sodium dodecyl sulfate reducing sample buffer (25 µl/well). The contents of three wells were combined and analyzed by Western blotting using Cat S antibody.
Elastase and Collagenase Assay
Protease assays were was performed as described,15,20
with minor modification. The procedures of preparing the lysates, plasma membranes, cytosols, and conditioned media were identical to those described above. Total protein (100 µg) from each sample was incubated with 1 mg/ml of Elastin-Congo Red (24 hours, for elastase assay) or 500 µg/ml of FITC-labeled type I collagen (6 hours, collagenase assay). Reactions were performed in the absence or presence of LHVS (5 nmol/L), E64 (20 µmol/L), Cyst C (1 µg/ml), and GM6001 (10 µmol/L). Procedural details are described elsewhere.6
We also prepared the plasma membrane from HSMCs cultured for 24 hours in the presence or absence of 400 U/ml of IFN- and 10 ng/ml of IL-1ß to examine their effect on elastolytic activity in the presence or absence of 5 nmol/L of LHVS.
Quantitative Real-Time Reverse Transcriptase (RT)-Polymerase Chain Reaction (PCR)
After being cultured in serum-free Dulbecco’s modified Eagle’s medium, the HSMCs were stimulated with or without 400 U/ml of IFN- and 10 ng/ml of IL-1ß for 24 hours. After extraction of total RNA, 20 ng of cellular RNA was analyzed for the Cat S mRNA by measuring the specific fluorescence signal from the TaqMan probe during quantitative real-time RT-PCR as previously described.6
The primer and probe used here included forward primer (5'-AGGGAACTCATCAAAGACATCACTT-3'), reverse primer (5'-GGGAATGCACTCATACGATCTG-3'), and probe (5'-TCACTGGTCATGTCTCCCAGGT-GGTTC-3'). Each mRNA quantity was normalized in regard to its respective GAPDH mRNA quantity.
Statistical Analysis
Values were expressed as means ± SE. Statistical analysis was performed by one-way analysis of variance followed by Scheffé’s multiple comparison. A value of P < 0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
To examine the function of Cat S in SMC invasion across the reconstituted ECM barrier, an SMC invasion assay was performed in the presence or absence of the selective Cat S inhibitor LHVS.10
As shown in Figure 1A
, 5 nmol/L of LHVS significantly inhibited platelet-derived growth factor-BB-directed HSMC invasion through type I collagen gel (27.9%). Similar to the LHVS, a synthetic inhibitor for a broader spectrum of CPs, 20 µmol/L of E64 showed a comparable level of inhibition of HSMC invasion (29.5%, Figure 1A
). Endogenous inhibitor Cyst C inhibits a spectrum of CPs but has the highest affinity for Cat S.21
In this in vitro assay, Cyst C at a physiological concentration of 1 µg/ml significantly inhibited HSMC invasion (26.5%, Figure 1A
). In contrast, 5 nmol/L of LHVS, 20 µmol/L of E64, and 1 µg/ml of Cyst C almost completely inhibited HSMC invasion through elastin gel by 91.5%, 92.1%, and 84.6%, respectively (Figure 1B)
. The MMP inhibitor GM6001 (10 µmol/L) significantly blocked HSMC invasion through type I collagen gel (56.5%, Figure 1A
) much more strongly than LHVS and E64 did, although GM6001 had no effect on HSMC invasion through elastin gel (Figure 1B)
. In addition, we observed that either LHVS (5 nmol/L) or E64 (20 µmol/L) combined with GM6001 (10 µmol/L) significantly increased the inhibition of HSMC invasion through type I collagen gel compared to that of the inhibitory effect by LHVS or E64 alone (83.9% and 87.5% inhibition, respectively) (Figure 1A)
. There was no effect on the HSMC invasion through either type I collagen gel or elastin gel in the presence of the SP inhibitor PMSF (2 mmol/L) (Figure 1, A and B)
. Compared with control, the addition of LHVS (5 nmol/L), E64 (20 µmol/L), or Cyst C (1 µg/ml) demonstrated no significant differences in HSMC adhesion onto the type I collagen, denatured type I collagen, fibronectin, elastin, or vitronectin (data not shown). In addition, we also observed that these CP inhibitors had no effect on HSMC migration across type I collagen elastin thin-coated filters (data not shown).
|
We examined the distribution of Cat S and K in SMCs derived from various species (HSMCs, RSMCs, and BSMCs). As shown in Figure 2, A and C
, the 28-kd active form of Cat S10
was detected in plasma membrane fractions as well as whole lysates from SMCs but not in the cell-cultured media or cytosol fractions. In contrast, the 29-kd active form of Cat K10
was detected in the whole cell lysates, cultured media, and cytosol fractions but not in the plasma membrane fractions (Figure 2, B and D)
. Western blot analysis of the plasma membrane and cytosol fractions from HSMCs and RSMCs for Cat B, L, and D showed that their latent forms (40 kd for Cat B, 42 kd for Cat L, and 42 kd for Cat D) were detected both in the plasma membrane and cytosol fractions, and the 25-kd active forms of Cat B and 27-kd active forms of Cat D were detected only in their cytosol fractions (Figure 2, E–G)
. To test the hypothesis that Cat S is localized at the cell surface, SMCs were subjected to surface biotinylation in conjunction with Western blotting using the pAb to Cat S. As shown in Figure 2H
, the active form of Cat S was precipitated with avidin-agarose after the cell surface was labeled using biotin. The latent forms of Cat B and Cat L were also precipitated with avidin-agarose after the cell surface was labeled using biotin (data not shown).
|
, a punctuated pattern representing clusters of Cat S was observed on the surface of HSMCs, BSMCs, and RSMCs (Figure 3A
, top). Usually three to five patches were observed on each cell, although their number varied from 0 to 7 in unstimulated SMCs. In contrast, Cat K staining showed a completely different pattern in HSMCs, BSMCs, and RSMCs with positive spots uniformly distributed along the cell body (Figure 3A
, bottom). As shown in Figure 3B
, Cat B, L, and D staining was concentrated in the perinuclear region in HSMCs and RSMCs. The staining was specific because no signal was detected using secondary antibody alone or the corresponding nonimmune antibody (data not shown).
|
As shown in Figure 4A
, the conditioned media from SMCs cultured in serum-free medium for 24 hours exhibited little or no elastolytic activity, whereas the SMC plasma membranes as well as cytosol fractions showed potential elastolytic activity (Figure 4A)
. Furthermore, LHVS, E64, or Cyst C significantly reduced the degradation of elastin by incubation with membrane fractions from HSMCs by 74%, 78.6%, or 69%, respectively (Figure 4B)
. The degradation of elastin by the plasma membrane was slightly reduced by GM6001 (data not shown). In addition, we observed that LHVS had no effect on the elastolytic activity of the cytosol fraction, although E64 and Cyst C significantly attenuated its activity (Figure 4C)
. We also observed that LHVS as well as E64 and Cyst C significantly reduced the degradation of type I collagen induced by the membrane fractions from HSMCs by 28%, 31.8%, and 29.3%, respectively, although they did so to a lesser extent than they inhibited the elastin degradation (Figure 4D)
. GM6001 significantly inhibited the collagenolytic activity of the HSMC plasma membrane (57.9%, Figure 4D
).
|
As shown in Figure 5A
, the plasma membrane fractions obtained from HSMCs stimulated with IFN- (400 U/ml) or IL-1ß (10 ng/ml) significantly augmented the degradation of elastin (3.6-fold and 2.4-fold, respectively) compared with an unstimulated control. Interestingly, the increased elastolytic activity stimulated by IFN- or IL-1ß was significantly reduced by treatment with LHVS (70% or 78%, respectively; Figure 5A
). To further determine whether the response of SMCs to proinflammatory cytokines was representative of increasing the active form of Cat S on the cell surface, the content of Cat S in the plasma membrane fractions was determined after treatment of HSMCs with IFN- or IL-1ß. As shown in Figure 5B
, the treatment with IFN- (400 U/ml) or IL-1ß (10 ng/ml) for 24 hours significantly increased the level of the active form of Cat S protein by 3.4- or 2.1-fold, respectively, compared with the control. Furthermore, it was reconfirmed by Western blot of the lysate that much greater levels of the active form of Cat S were detected in the lysates (Figure 5C)
. However, we did not detect the active form of Cat S in the fractions of cytosol and media (Figure 5C)
. It is consistent with the data from immunofluorescence staining and confocal microscopy analysis that IFN- increased the numbers of patches representing clusters of Cat S between 10 to 20 on HSMC surface compared with unstimulated control cells (Figure 3A
, middle). The data from real-time RT-PCR demonstrated that the Cat S mRNA was expressed in the unstimulated HSMCs, and both IFN- (400 U/ml) and IL-1ß (10 ng/ml) significantly increased its expression (5.0-fold and 3.4-fold, respectively; Figure 5D
).
|
Previous studies had demonstrated that integrins ß3 and ß1 on the SMC surface not only promote cell migration but also serve as receptors for proteases such as MMP-2, facilitating their expression in a functionally active form.19,22,23
These findings prompted us to hypothesize that the localization of Cat S on the surface of the SMCs may be mediated by integrins. To assess this idea, we first analyzed cell lysates prepared from HSMCs and RSMCs by sequential immunoprecipitation with antibodies against integrins such as ß3, ß1, ß3, or ß5, followed by immunoblotting with antibody to Cat S. As shown in Figure 6A
, a 28-kd immunoreactive protein from the immunoprecipitation using the antibodies to ß3, , and ß3 was detected on the Western blot, corresponding to the predicted size of the active form of Cat S. The results from immunoprecipitation using antibody to Cat S was analyzed by Western blot using antibodies to and ß3. As shown in Figure 6, B and C
, and ß3 integrins were precipitated with Cat S antibody. To strengthen this finding, double-label immunofluorescence staining using confocal microscopy was performed in RSMCs and HSMCs. As shown in Figure 7
, we observed that the greater part of the clustered ß3 integrin was co-localized with Cat S on the cell surface. The data from Cat S binding assay showed that the active form of Cat S was capable of binding to the immobilized integrin ß3 (Figure 6D)
. We next assessed whether the active form of Cat S that binds to the integrins could affect SMC adhesion on ECM. The pretreatment of SMCs with an exogenous active form of Cat S at concentrations from 1 to 5 µg/ml had no effect on SMC adhesion to the type I collagen-, denatured-type I collagen-, elastin-, and vitronectin-coated plates compared with untreated controls (data not shown).
|
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
It has been demonstrated by immunostaining observations that cells migrating into and accumulating within developing intimal plaques in humans synthesize the potent elastase Cat S.10 Recent studies have shown that Cat S is overexpressed in atherosclerotic and neointimal lesions in human and animal models, and Cat S deficiency prevents the degradation of elastic lamina and type I collagen in aortal atherosclerotic lesion of LDL receptor-deficient mice.6,10,25 These findings suggest that Cat S may participate in ECM degradation and SMC migration during the development of intimal plaque or hyperplasia. To establish the role of the proteases in the SMC movement into the subendothelial space in the vascular wall, in vitro models of chemoattractant-directed SMC migration across ECM-coated porous filters, which function as ECM barriers, in the presence or absence of the associated inhibitors have frequently been used.15,16 In the present study we demonstrated that a selective Cat S inhibitor, LHVS,10 as well as a synthetic broad spectrum CP inhibitor, E64, and a natural inhibitor, Cyst C,21 blocked SMC invasion across type I collagen gel, although with a lesser inhibitory effect than that of an MMP inhibitor, GM6001. Interestingly, LHVS almost completely inhibited SMC invasion across an elastin barrier, which was comparable to the action of E64 and Cyst C. In contrast to the Cat S inhibitor, a SP inhibitor, PMSF, had no effect on SMC invasion across type I collagen gel or elastin gel. These data suggest that among SMC-derived CP, Cat S in particular may play an important role in SMC migration from the media into the subendothelial space by facilitating the proteolytic degradation of the elastin-rich matrix. Additionally, the combination of GM6001 with LHVS or E64 has been demonstrated to inhibit the invasion of SMCs through a collagen lattice barrier more effectively than each inhibitor alone inhibits such invasions. This result suggested that not only MMPs but also Cat S are involved in SMC migration through type I collagen and that the combination of MMP and CP inhibitor, particularly the Cat S inhibitor, may provide a more effective and useful method of experimental and clinical therapy of restenosis after angioplasty. As in this study, the inhibition of Cat S had no effect on SMC adhesion to ECM or on SMC migration through an ECM thin-coated membrane. This result suggests that Cat S likely has a role in mediating the proteolytic process during SMC invasion through elastin or collagen matrix but does not have a role in mediating the migration process itself.
Evidence from several studies indicates that cells can concentrate proteases such as pro-MMP-219,22 and urokinase-type plasminogen activator24 at specific sites on their surface, allowing for the degradation of ECM components. Here, we demonstrated for the first time, based on the observations of Western blotting analysis of subcellular fractions, that the active form of Cat S exists on the SMC plasma membrane but not in the cytosol. In contrast, the active forms of Cat K, B, L, and D were not detected on the SMC plasma membranes. Immunofluorescence staining with cathepsin-specific antibodies revealed punctate labeling of Cat S on the periphery of the SMCs, in contrast with Cat K in which positive spots were uniformly distributed along the cell body. Cat B, L, and D staining was concentrated in the intracellular region, particularly the perinuclear region in SMCs. These results suggest that Cat B, D, K, and L have different spatial regulation and molecular functions during SMC adhesion, migration, and invasion.
Previous immunostaining data of Sukhova and colleagues on Cat S10
suggest that Cat S has a lysosomal distribution. However, they did not show any direct evidence to illustrate intracellular localization of Cat S. In addition, the results of Western blotting analysis by Sukhova and colleagues10
reported the secretion of Cat S by SMCs from the saphenous vein into the media and the presence of precursor of Cat S in the cell lysate (applied 0.3 mg protein). In this study, we have reported that the active form of Cat S was detected in the membrane fractions of aortic SMCs (human, rat, and bovine) but not in the media (applied 0.06 mg protein). The data from Watari’s group26
had demonstrated that the active form of Cat S (28 kd) was detected in cell lysates from control and tumor necrosis factor--treated cells, whereas pro-Cat S (
37 kd) protein was detected only in conditioned medium from cultures treated with tumor necrosis factor-. It has also been reported that both pro- and active form of Cat S were secreted into the culture medium after 5 days in culture.27
Therefore the different results between Sukhova and colleagues10
previous and our present studies regarding the distribution of Cat S seem to be attributable to the different applied amounts of total protein for Western blotting assay. It is also possible that the different results might be contributable to the different source of SMCs (saphenous vein or aorta).
The findings of the biotinylation studies on the cell membrane support and extend the existence of the active form of Cat S outside the surface of the SMCs. Interestingly, we observed that the SMC membrane fractions showed potential elastolytic and collagenolytic activities, and their abilities were significantly reduced by LHVS as well as E64. Additionally, we also demonstrated that there was no effect of LHVS on the elastolytic activity of the cytosol fraction from SMCs. These results, together with the immunofluorescence staining of SMCs, suggested that Cat S is a major contributor to the elastolytic activity of SMC membrane but not to that of the cytosol. In addition, these findings indicate that the active form of Cat S on the SMC surface, where the cell makes contact with the ECM, facilitates ECM degradation and SMC migration.
Several lines of investigation demonstrated that among CPs, Cat S expression and activity were up-regulated by inflammatory cytokines, such as IFN-, in mice peritoneal macrophage, and human cervical SMCs.26-28
The present study shows that IL-1ß and IFN- up-regulated vascular SMC expression of the active form of Cat S protein and accumulation on the cell surface and enhanced its elastolytic activity. This result suggests that overexpression and accumulation of Cat S stimulated with the inflammatory cytokine on SMC plasma membrane may promote the tunica medial SMC degradation of ECM and migration through the elastic lamina to the intimal place during the inflammatory arterial diseases.
Earlier results from our laboratory and from others demonstrated that the ß3 integrin that was expressed on the surface as a receptor for several proteases was involved in SMC adhesion and migration.16,19,22
In this study, we clearly illustrated the distinctive cell surface localization of Cat S at the periphery of the cell, often at cell protrusions. Apparently, the clustering of Cat S and ß3 integrin, demonstrated in this study by confocal microscopy and co-precipitation, may represent a means to most efficiently and specifically decorate discrete regions of SMCs with the mature Cat S enzyme in its proteolytically active form. However, it should be noted that Cat S and ß3 integrin are partially co-localized and clustered at SMC surfaces because double-staining and confocal microscopy confirmed that there was no full overlap of the red and green colors in each cell. In fact, we observed that immunoprecipitation of SMC lysates with monoclonal antibody to ß1 integrin precipitated the small amount of the active form of Cat S, suggesting that among the integrins, ß3 integrin is the most efficient but not unique in its ability to associate with the active form of Cat S. To our surprise, we failed to observe any effect of the pretreatment of HSMCs with the active form of Cat S on SMC adhesion to vitronectin or denatured-type I collagen on which SMC attaches through ß3 integrin.16
These findings, in combination with an earlier report that Cat S lacks an arginine-glycine-aspartic acid (RDG) sequence29
commonly found in ligands for ß3 integrin, indicates that the ability of Cat S to associate with ß3 integrin appears to be distinct from other ß3 integrin-directed ligands. Although it is not clear how ß3 integrin interacts with the domain of Cat S, throughout the past few years, various other unrelated non-RGD ligands of ß3 integrin have also been recognized, including CD31/PECAM-130
and MMP-2.19,22
The co-localization of Cat S and ß3 integrin on SMCs is consistent with the recent evidence that proteases and their receptors may be functionally associated with integrin. Indirectly supporting this concept is the present observation from the Cat S binding assay that the soluble human recombinant active form of Cat S is capable of binding to immobilized receptor of integrin ß3. However, no biochemical evidence exists to suggest that these receptors are structurally linked on the cell surface.
In summary, our data show that Cat S and its proposed receptor integrin ß3 are both targeted to the same membrane microdomains in vascular SMCs. This finding provides an elegant mechanism to restrict the proteolysis of the ECM to a limited microenvironment of the cell. This study also raises numerous topics for further investigation, such as the secretion and maturation of cathepsins, and underscores the need to consider Cat S as a molecular therapeutic target in vascular diseases such as atherosclerosis and restenosis after angioplasty.
|
Footnotes |
|---|
Supported in part by the Ministry of Education, Science, and Culture, Japan (Scientific Research Fund grant no. 13671182).
Accepted for publication October 19, 2005.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  X. W. Cheng, T. Murohara, M. Kuzuya, H. Izawa, T. Sasaki, K. Obata, K. Nagata, T. Nishizawa, M. Kobayashi, T. Yamada, et al. Superoxide-Dependent Cathepsin Activation Is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotensin II Type 1 Receptor Blocker Treatment Am. J. Pathol., August 1, 2008; 173(2): 358 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. M. Lutgens, K. B. J. M. Cleutjens, M. J. A. P. Daemen, and S. Heeneman Cathepsin cysteine proteases in cardiovascular disease FASEB J, October 1, 2007; 21(12): 3029 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Suganuma, V. R. Babaev, M. Motojima, Y. Zuo, N. Ayabe, A. B. Fogo, I. Ichikawa, M. F. Linton, S. Fazio, and V. Kon Angiotensin Inhibition Decreases Progression of Advanced Atherosclerosis and Stabilizes Established Atherosclerotic Plaques J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2311 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kitamoto, G. K. Sukhova, J. Sun, M. Yang, P. Libby, V. Love, P. Duramad, C. Sun, Y. Zhang, X. Yang, et al. Cathepsin L Deficiency Reduces Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Knockout Mice Circulation, April 17, 2007; 115(15): 2065 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. W. Cheng, K. Obata, M. Kuzuya, H. Izawa, K. Nakamura, E. Asai, T. Nagasaka, M. Saka, T. Kimata, A. Noda, et al. Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure Hypertension, November 1, 2006; 48(5): 979 - 987. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
